Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase Ib/II Clinical Trial of TCC1727 in Combination With Benmelstobart/Olaparib/Topotecan for Advanced Solid Tumors

NCT07371663 is registered in ClinicalTrials.gov with Beijing Tide Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07371663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07371663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase Ib/II Clinical Trial of TCC1727 in Combination With Benmelstobart/Olaparib/Topotecan for Advanced Solid Tumors
Lead sponsor
Beijing Tide Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 3, 2025
Completion date
June 30, 2029
Enrollment
266 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, gastric (stomach) cancer, malignant melanoma, nsclc (advanced non-small cell lung cancer), solid cancers